The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis
Abstract
Objective: Transient B cell depletion with the monoclonal anti‐CD20 antibody rituximab has resulted in favorable clinical responses in patients with rheumatoid arthritis (RA). However, little is known about the regeneration profile of different peripheral B cell subpopulations. The aim of this study was to delineate the regeneration profile of different B cell subsets in the peripheral blood after selective anti‐CD20–mediated B cell depletion. Methods: Seventeen patients with RA refractory to standard therapy were treated with rituximab. Patients 1–6 received 4 weekly infusions of rituximab at a dose of 375 mg/m 2, and patients 7–17 received 2 infusions of rituximab (1,000 mg), 2 weeks apart. Four‐color staining was performed at several time points, using CD38, IgD, and CD27 in addition to other cell surface markers. In one patient, the mutational status of the immunoglobulin receptor was examined. Results: The analysis revealed a distinct pattern of B cell regeneration. The first wave of repopulating B cells were immature B cells (CD38 high,IgD+,CD10+,CD24 high), the immunoglobulin receptors of which were not yet somatically mutated. In parallel, a recirculation of plasma cells was observed. Later, the number of naive B cells increased, and these cells predominated in the peripheral blood B cell pool. CD27+ memory B cells showed a slow and delayed repopulation, and the level of these cells stayed significantly reduced (<50%) compared with baseline values, for more than 2 years. Conclusion: Our findings provide evidence for a characteristic regeneration pattern of B cell subpopulations, with long‐lasting modulation of B cell subset composition, after selective anti‐CD20–mediated B cell depletion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Klein, U., Rajewsky, K., & Küppers, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1679 · Cited by 1,154
van der Heijde, D. M., van 't Hof, M. A., van Riel, P. L., Theunisse, L. A., Lubberts, E. W., van Leeuwen, M. A., van Rijswijk, M. H., & van de Putte, L. B. (1990) · Annals of the Rheumatic Diseases · doi:10.1136/ard.49.11.916 · Cited by 1,087
Weller, S. (2004) · Blood · doi:10.1182/blood-2004-01-0346 · Cited by 814
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711
RHEUMATOID ARTHRITIS: A DISEASE OF T-LYMPHOCYTE/MACROPHAGE IMMUNOREGULATION
Janossy, G., Duke, O., Poulter, L. W., Panayi, G., Bofill, M., & Goldstein, G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91107-7 · Cited by 655
Cited by
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Self-citationNew therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes
Cerutti, A., Cols, M., & Puga, I. (2013) · Nature Reviews Immunology · doi:10.1038/nri3383 · Cited by 777
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 734
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., & Bennett, C. L. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70161-5 · Cited by 447
Spencer, J., Perry, M. E., & Dunn-Walters, D. K. (1998) · Immunology Today · doi:10.1016/s0167-5699(98)01308-5 · Cited by 407
Weill, J.-C., Weller, S., & Reynaud, C.-A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132607 · Cited by 405
van Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25033 · Cited by 371
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Anolik, J. H., Barnard, J., Owen, T., Zheng, B., Kemshetti, S., Looney, R. J., & Sanz, I. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22810 · Cited by 333
B‐lymphocyte contributions to human autoimmune disease
Yanaba, K., Bouaziz, J., Matsushita, T., Magro, C. M., St.Clair, E. W., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326
Novel Human Transitional B Cell Populations Revealed by B Cell Depletion Therapy
Palanichamy, A., Barnard, J., Zheng, B., Owen, T., Quach, T., Wei, C., Looney, R. J., Sanz, I., & Anolik, J. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801859 · Cited by 300
Self-citationRole of B Cells in Multiple Sclerosis and Related Disorders
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., Hauser, S. L., & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation (2021) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 283
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192
B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
Bugatti, S., Vitolo, B., Caporali, R., Montecucco, C., & Manzo, A. (2014) · BioMed Research International · doi:10.1155/2014/681678 · Cited by 170
Metadata
- Authors
- Roll, P., Palanichamy, A., Kneitz, C., Dorner, T., & Tony, H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-07-25
- Volume
- 54
- Issue
- 8
- Pages
- 2377-2386
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2077286174
- Cited by
- 321
- References
- 33
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.